Genyx Medical, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Financing commitment of $3 mil. is received from Brentwood Venture Capital. Funds will be used to support development of Genyx parent company Micro Therapeutics' Embolyx technology under a cross-licensing agreement for use as a urethral bulking agent to treat stress urinary incontinence. Embolyx, which is composed of a biocompatible polymer of ethylene vinyl alcohol and contrast material dissolved in a dimethyl sulfoxide carrier for injection into the body, is also being developed by MTI for the endovascular treatment of arterio-venous malformations and aneurysms in the brain ("The Gray Sheet" Nov. 24, 1997, In Brief). Genyx was formed in November 1997 to explore use of Embolyx in urological and gynecological applications ("The Gray Sheet" Dec. 15, 1997, p. 21)